Category: Consumer goods
Quick infos Headquarters: Philadelphia, Pennsylvania, United States Trade prices Volume: Market Cap: 82.16M Prev closed: Open: High: Low: 52 week low: 52 week high: Dividends: Next ER: August 13, 2021
Earnings History Date EPS / Forecast Revenue / Forecast November 10, 2021 August 13, 2021 -0.0277 / -0.02779.7M / -1MBeat! May 14, 2021 -0.13 / -0.03272M / -3MBeat! March 25, 2021 -0.0158 / -0.03810.2M / -2MBeat! March 4, 2021 - / -0.038- / -2MBeat! view more
Historical Data Date Price Open High Low Vol Change ER Aug 13, 2021 4.37 4.58 4.67
4.33
127.10K -4.17% Aug 12, 2021 4.56 4.60 4.64
4.52
26.49K -0.44% Aug 11, 2021 4.58 4.57 4.63
4.55
14.90K 0% Aug 10, 2021 4.58 4.56 4.65
4.56
34.90K -0.22% Aug 9, 2021 4.59 4.65 4.65
4.57
19.91K -1.08% Aug 6, 2021 4.64 4.71 4.75
4.64
25.03K -2.32% Aug 5, 2021 4.75 4.64 4.75
4.64
42.70K 2.15% Aug 4, 2021 4.65 4.64 4.79
4.62
85.25K -2.11% Aug 3, 2021 4.75 4.65 4.83
4.65
36.21K 0.42% Jul 30, 2021 4.73 4.65 4.74
4.64
34.70K 0.64% view more
News
AIM ImmunoTech's Ampligen's shows encouraging prophylactic effect against COVID-19 seekingalpha.com Aug 27, 2020 10:20 pm AIM ImmunoTech reports Q2 results seekingalpha.com Aug 17, 2020 7:11 pm AIM ImmunoTech teams up with Roswell Park for combo trial in COVID-19 patients with cancer seekingalpha.com Jul 9, 2020 7:09 pm
Mid-Afternoon Market Update: Dow Tumbles 8%; AIM ImmunoTech Shares Spikes Higher benzinga.com Mar 9, 2020 7:03 pm AIM ImmunoTech's Drug Ampligen to Be Tested by Japan's National Institute of Infectious Diseases as a Potential Treatment for the New SARS Coronavirus (SARS-CoV-2) Responsible for the New Human Infectious Disease COVID-19 finance.yahoo.com Mar 9, 2020 9:03 am AIM ImmunoTech up 66% premarket on Ampligen testing in Japan for COVID-19 seekingalpha.com Mar 9, 2020 9:03 am
AIM ImmunoTech Inc bloomberg.com Feb 29, 2020 1:02 pm AIM ImmunoTech gets China entry boost for coronavirus drug seekingalpha.com Feb 27, 2020 1:02 pm WLL, SPEX, CODX and AIM among midday movers seekingalpha.com Feb 27, 2020 1:02 pm AIM ImmunoTech Joins with ChinaGoAbroad for an Ampligen China Entry Against COVID-19, the New SARS-like Coronavirus Disease Epidemic finance.yahoo.com Feb 27, 2020 8:02 am AIM ImmunoTech Issues Stockholder Update on the Potential Role of Ampligen for Use Against the Wuhan Coronavirus Epidemic finance.yahoo.com Feb 18, 2020 7:02 am
AIM ImmunoTech Inc. Announces a Second DoD Award, This One of $8.3 Million, to Fund Phase 2 Clinical Trial to Study Am bloomberg.com Feb 11, 2020 6:02 pm AIM ImmunoTech joins Russell Microcap Index seekingalpha.com Jun 29, 2020 7:11 pm AIM ImmunoTech files provisional patent for the use of Ampligen in COVID-19 seekingalpha.com Jun 11, 2020 9:27 pm AIM ImmunoTech +34% after FDA authorizes ampligen trial in COVID-19 patients seekingalpha.com May 14, 2020 8:20 pm AIM ImmunoTech EPS misses by $0.12 seekingalpha.com May 14, 2020 6:56 pm AIM ImmunoTech to investigate vaping device with Ampligen for COVID-19 seekingalpha.com May 14, 2020 8:19 am AIM Immunotech nabs NCI grant to study Ampligen; shares up 8% premarket seekingalpha.com Apr 6, 2020 7:39 pm AIM ImmunoTech EPS beats by $1.11, misses on revenue seekingalpha.com Mar 31, 2020 6:51 pm Coronavirus plays on the move premarket seekingalpha.com Mar 31, 2020 5:22 am AIM Dividends Ex-Dividend Amount Announced Date Record Date Payment Date Jun 14, 2017 0.8 Dec 28, 2018 Mar 15, 2017 0.8 Mar 31, 2017 Sep 14, 2016 0.8 Sep 30, 2016 Jun 14, 2016 0.8 Jun 30, 2016 Mar 15, 2016 0.76 Mar 31, 2016 view more
Talk about AIM ImmunoTech Inc below in comments section below. Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above.
Share it with fellow traders:
or join discussions in FB below
(
FB comments )
If you are looking for News & events, Press Release, they are available on their Investors Relations site.
If you want to help pay for server cost or for improving this tool. You can send it via Paypal .
Buy on Amazon In the world of investing, slow and steady wins the race. With this mantra in mind, trusted author and finance guru Eric Tyson is back with the latest edition of the #1 bestselling book, Investing For Dummies, to help you achieve your investment goals.
